Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results

R Pebody, F Warburton, J Ellis, N Andrews, A Potts, S Cottrel, J Johnston, A Reynolds, R Gunson, C Thompson, M Galiano, C Robertson, R Byford, N Gallagher, M Sinnathamby, I Yonova, S Pathirannehelage, M Donati, C Moore, S de LusignanJ McMenamin, M Zambon

Research output: Contribution to journalArticle

76 Citations (Scopus)
11 Downloads (Pure)

Abstract

The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6-94.3) against influenza B and 41.5% (95% CI: -8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalEurosurveillance
Volume21
Issue number38
DOIs
Publication statusPublished - 22 Sep 2016

Fingerprint

Influenza Vaccines
Human Influenza
Primary Health Care
Confidence Intervals
Attenuated Vaccines
Inactivated Vaccines
United Kingdom
Immunization Programs
Victoria
Vaccination
Referral and Consultation
Vaccines

Keywords

  • influenza vaccine
  • influenza immunisation
  • public health policy

Cite this

Pebody, R ; Warburton, F ; Ellis, J ; Andrews, N ; Potts, A ; Cottrel, S ; Johnston, J ; Reynolds, A ; Gunson, R ; Thompson, C ; Galiano, M ; Robertson, C ; Byford, R ; Gallagher, N ; Sinnathamby, M ; Yonova, I ; Pathirannehelage, S ; Donati, M ; Moore, C ; de Lusignan, S ; McMenamin, J ; Zambon, M. / Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom : 2015/16 end-of-season results. In: Eurosurveillance. 2016 ; Vol. 21, No. 38. pp. 1-11.
@article{2d64beba34be45c2ac80e0dbf1f413b8,
title = "Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results",
abstract = "The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4{\%} (95{\%} confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5{\%} (95{\%} CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2{\%} (95{\%} CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6{\%} (95{\%} CI: 25.1 to 76.0) against any influenza, 81.4{\%} (95{\%} CI: 39.6-94.3) against influenza B and 41.5{\%} (95{\%} CI: -8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.",
keywords = "influenza vaccine, influenza immunisation, public health policy",
author = "R Pebody and F Warburton and J Ellis and N Andrews and A Potts and S Cottrel and J Johnston and A Reynolds and R Gunson and C Thompson and M Galiano and C Robertson and R Byford and N Gallagher and M Sinnathamby and I Yonova and S Pathirannehelage and M Donati and C Moore and {de Lusignan}, S and J McMenamin and M Zambon",
note = "This article is copyright of The Authors, 2016.",
year = "2016",
month = "9",
day = "22",
doi = "10.2807/1560-7917.ES.2016.21.38.30348",
language = "English",
volume = "21",
pages = "1--11",
journal = "Eurosurveillance",
issn = "1560-7917",
number = "38",

}

Pebody, R, Warburton, F, Ellis, J, Andrews, N, Potts, A, Cottrel, S, Johnston, J, Reynolds, A, Gunson, R, Thompson, C, Galiano, M, Robertson, C, Byford, R, Gallagher, N, Sinnathamby, M, Yonova, I, Pathirannehelage, S, Donati, M, Moore, C, de Lusignan, S, McMenamin, J & Zambon, M 2016, 'Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results', Eurosurveillance, vol. 21, no. 38, pp. 1-11. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348

Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom : 2015/16 end-of-season results. / Pebody, R; Warburton, F; Ellis, J; Andrews, N; Potts, A; Cottrel, S; Johnston, J; Reynolds, A; Gunson, R; Thompson, C; Galiano, M; Robertson, C; Byford, R; Gallagher, N; Sinnathamby, M; Yonova, I; Pathirannehelage, S; Donati, M; Moore, C; de Lusignan, S; McMenamin, J; Zambon, M.

In: Eurosurveillance, Vol. 21, No. 38, 22.09.2016, p. 1-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom

T2 - 2015/16 end-of-season results

AU - Pebody, R

AU - Warburton, F

AU - Ellis, J

AU - Andrews, N

AU - Potts, A

AU - Cottrel, S

AU - Johnston, J

AU - Reynolds, A

AU - Gunson, R

AU - Thompson, C

AU - Galiano, M

AU - Robertson, C

AU - Byford, R

AU - Gallagher, N

AU - Sinnathamby, M

AU - Yonova, I

AU - Pathirannehelage, S

AU - Donati, M

AU - Moore, C

AU - de Lusignan, S

AU - McMenamin, J

AU - Zambon, M

N1 - This article is copyright of The Authors, 2016.

PY - 2016/9/22

Y1 - 2016/9/22

N2 - The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6-94.3) against influenza B and 41.5% (95% CI: -8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

AB - The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6-94.3) against influenza B and 41.5% (95% CI: -8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

KW - influenza vaccine

KW - influenza immunisation

KW - public health policy

U2 - 10.2807/1560-7917.ES.2016.21.38.30348

DO - 10.2807/1560-7917.ES.2016.21.38.30348

M3 - Article

C2 - 27684603

VL - 21

SP - 1

EP - 11

JO - Eurosurveillance

JF - Eurosurveillance

SN - 1560-7917

IS - 38

ER -